BRAF and Miyoshi myopathy: Selective inhibition of B-Raf with vemurafenib (Zelboraf; Roche) or dabrafenib (Tafinlar; Novartis) currently used in association with comibenitib (Cotellic; Roche) and trametinib (Mekinist; Novartis), has revolutionized the treatment of unresectable or metastatic melanoma (MM) patients bearing BRAF mutations2,3.